Search
-
The Dirk Remus Lab
… The Dirk Remus Lab Postdoctoral positions are available. Applicants with a strong interest in chromosome biology and with experience in protein biochemistry and/or yeast genetics should direct inquiries to Dirk Remus at [email protected] . Please include with your cover letter, your CV, and name/contact
-
Pathologist… Pathologist Job Title Assistant Attending Physician; Associate Director, Gastrointestinal Pathology Fellowship Program I am a board-certified anatomic and molecular pathologist with subspecialty training in gastrointestinal (GI) pathology. Part of my practice focuses on the surgical pathology of the
-
Pathologist
… Pathologist Job Title Médico adjunto asistente; Director asociado del Programa de Becas en Patología Gastrointestinal Soy patólogo anatómico certificado por la junta con formación subespecializada en patología gastrointestinal (GI). Parte de mi práctica profesional se concentra en la patología quirúrgica
-
News
… Monday, March 24, 2025 Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and progress. (1) Metastatic disease develops in about 50% of patients with surgically
-
-
The Craig Thompson Lab
… Job Title Postdoctoral fellow Email [email protected] Lab Phone 646-888-3285
-
The Lorenz Studer Lab
Our lab has pioneered the directed differentiation of human pluripotent stem cells into multiple specialized cell types of both the central and peripheral nervous system. The long-term goal is to develop a roadmap to re-create the full cellular diversity of the nervous system. In addition to cell fate, we are interested in defining the molecular pathways that control timing of human differentiation including cell fate specification, neuronal maturation and the programming and re-programming of cellular age in a dish.
… Deriving specific brain and spinal cord cell types from human PSCs Based on conserved developmental principles, we have developed a simple but highly efficient platform to convert human PSCs into neural tissue. We have shown that dual-SMAD inhibition via small molecule inhibitors of BMP and TGFb/Activin
-
News
Memorial Sloan Kettering Cancer Center (MSK) researchers presented the results of a randomized phase III trial at today’s press program for the European Society for Medical Oncology’s 2018 Congress in Munich, Germany. The results demonstrated that a combination of the immune checkpoint blocker avelumab (Bavencio®) and the tyrosine kinase inhibitor (TKI) axitinib (Inlyta®) can significantly improve progression-free survival (PFS) in people who have been previously untreated for advanced renal cell carcinoma (RCC).
… Sunday, October 21, 2018 Memorial Sloan Kettering Cancer Center (MSK) researchers presented the results of a randomized phase III trial at today’s press program for the European Society for Medical Oncology ’s 2018 Congress in Munich, Germany. The results demonstrated that a combination of the immune
-
Video
Health Education Seminar | The Society of Memorial Sloan Kettering Cancer Center
… Health Education Seminar | The Society of Memorial Sloan Kettering Cancer Center
-
The John Petrini Lab
… Tea will be served at 10:45 a.m. , immediately preceding the seminar. Audience This seminar is open to the research community. Location Memorial Sloan Kettering Cancer Center Rockefeller Research Laboratories 430 East 67th Street RRL-120 (Auditorium) New York, NY 10065 Speaker(s) Akanksha Thawani,